The operational demands of psychedelic clinical trials are often determined long before the first participant arrives for treatment. Decisions about the compound, route of administration, treatment frequency, psychological support, and safety monitoring shape the resources, workflows, and procedures sites will...
Expertise: Neuroscience 46 results
Neuroscience
CNS Summit
Neuroscience
AES Annual Meeting
Neuroscience
ECNP Congress Munich
Neuroscience
16th European Epilepsy Congress
Neuroscience
AAIC
Psychedelic drug development is moving into a more consequential phase. Compounds such as MDMA, psilocybin, LSD, and other psychoactive agents continue to be explored for serious mental health conditions, including post-traumatic stress disorder, treatment-resistant depression, major depressive disorder, and substance...